August 18, 2017 08:31 AM EDTUpdated 09:34 AM
Bioregnum
Opinion

Pre­emp­tive sham­ing as­sault on No­var­tis’ CAR-T pi­o­neer un­der­scores a dis­con­nect on R&D costs

It’s no se­cret that tax­pay­ers fund a lot of the ba­sic sci­ence work done in the US. But should that ear­ly re­search sup­port for new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Pfiz­er gets an FDA win in he­mo­phil­ia af­ter a rough week

VC firm tar­gets $35M sec­ond fund to back star­tups led by sci­en­tists

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Stealth Bio­Ther­a­peu­tics CEO dis­cuss­es sur­prise ad­comm sup­port for ul­tra-rare dis­ease drug

Lil­ly fol­lows the trend of new AI hires; Pfiz­er fills key UK po­si­tion as ac­tivist hub­bub swells

Sanofi lands on pri­vate eq­ui­ty firm CD&R as po­ten­tial buy­er of con­sumer health unit

A service from the Financial Times